By Mary Romeo, Staff Writer | Apr 26, 2019 | 11:20 PM GMT
Editor's Note: This article was updated on May 1, 2019 at 8:36 PM GMT
Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.
Read the full 305 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD